E-cadherin reactivity of 95 noninvasive ductal and lobular lesions of the breast: Implications for the interpretation of problematic lesions

American Journal of Clinical Pathology

Volumn 115, Issue 4, 2001, Pages 534-542

  Goldstein, Neal S ^a   Bassi, Deepa ^a   Watts, John C ^a   Layfield, Lester J ^b   Yaziji, Hadi ^a   Gown, Allen M ^c  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

^b UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^c PHENOPATH LABORATORIES   (United States)

Author keywords

Breast; Carcinoma; Ductal; E cadherin; Hyperplasia; In situ; Lobular

Indexed keywords

UVOMORULIN;

ARTICLE; BREAST CARCINOMA; BREAST EPITHELIUM; BREAST HYPERPLASIA; BREAST LESION; CARCINOMA IN SITU; CELL STRUCTURE; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; PRIORITY JOURNAL;

BENCHMARKING; BREAST; BREAST NEOPLASMS; CADHERINS; CARCINOMA IN SITU; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CARCINOMA, LOBULAR; DIAGNOSIS, DIFFERENTIAL; EPITHELIAL CELLS; FEMALE; HUMANS; TUMOR MARKERS, BIOLOGICAL;

EID: 0035062633     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/B0DD-4M7H-GJG1-7KCW     Document Type: Article

References (49)

1. Bear HD, Carter WH Jr, Grimes MM. Despite limited data, coexistent lobular carcinoma in situ should not be a contraindication to breast conservation for women with invasive breast carcinoma. Cancer. 2000;88:978-981.
2. Lishman SC, Lakhani SR. Atypical lobular hyperplasia and lobular carcinoma in situ: surgical and molecular pathology. Histopathology. 1999;35:195-200.
3. Bodian CA, Perzin KH, Lattes R. Lobular neoplasia: long term risk of breast cancer and relation to other factors. Cancer. 1996;78:1024-1034.
4. Fisher ER, Costantino J, Fisher B, et al. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) Protocol B-17: five-year observations concerning lobular carcinoma in situ. Cancer. 1996;78:1403-1416.
5. Walt AJ, Simon M, Swanson GM. The continuing dilemma of lobular carcinoma in situ. Arch Surg. 1992;127:904-907.
6. Page DL, Kidd TE Jr, Dupont WD, et al. Lobular neoplasia of the breast: higher risk for subsequent invasive cancer predicted by more extensive disease. Hum Pathol. 1991;22:1232-1239.
7. Salvadori B, Bartoli C, Zurrida S, et al. Risk of invasive cancer in women with lobular carcinoma in situ of the breast. Eur J Cancer. 1991;27:35-37.
8. Eusebi V, Foschini MP, Cook MG, et al. Long-term follow-up of in situ carcinoma of the breast with special emphasis on clinging carcinoma. Semin Diagn Pathol. 1989;6:165-173.
9. Temple WJ, Jenkins M, Alexander F, et al. Natural history of in situ breast cancer in a defined population. Ann Surg. 1989;210:653-657.
10. Frykberg ER, Santiago F, Betsill WL Jr, et al. Lobular carcinoma in situ of the breast. Surg Gynecol Obstet. 1987;164:285-301.
11. Page DL, Dupont WD, Rogers LW. Breast cancer risk of lobular-based hyperplasia after biopsy: "ductal" pattern lesions. Cancer Detect Prev. 1986;9:441-448.
12. Sunshine JA, Moseley HS, Fletcher WS, et al. Breast carcinoma in situ: a retrospective review of 112 cases with a minimum 10 year follow-up. Am J Surg. 1985;150:44-51.
13. Davis N, Baird RM. Breast cancer in association with lobular carcinoma in situ: clinicopathologic review and treatment recommendation. Am J Surg. 1984;147:641-645.
14. Fisher ER, Fisher B, Sass R, et al. Pathologic findings from the National Surgical Adjuvant Breast Project (Protocol No. 4), XI: bilateral breast cancer. Cancer. 1984;54:3002-3011.
15. Hutter RV. The management of patients with lobular carcinoma in situ of the breast. Cancer. 1984;53:798-802.
16. Rosen PP. Lobular carcinoma in situ and intraductal carcinoma of the breast. Monogr Pathol. 1984:59-105.
17. Tulusan AH, Egger H, Schneider ML, et al. A contribution to the natural history of breast cancer, IV: lobular carcinoma in situ and its relation to breast cancer. Arch Gynecol. 1982; 231:219-226.
18. Andersen JA, Fechner RE, Lattes R, et al. Lobular carcinoma in situ: (lobular neoplasia) of the breast (a symposium). Pathol Annu. 1980;15:193-223.
19. Lattes R. Lobular neoplasia (lobular carcinoma in situ) of the breast. Pathol Res Pract. 1980;166:415-429.
20. Rosen PP, Braun DW Jr, Kinne DW. The clinical significance of pre-invasive breast carcinoma. Cancer. 1980;46:919-925.
21. Andersen JA. Lobular carcinoma in situ of the breast: an approach to rational treatment. Cancer. 1977;39:2597-2602.
22. Andersen JA. Lobular carcinoma in situ: a long-term follow-up in 52 cases. Acta Pathol Microbiol Scand [A]. 1974;82:519-533.
23. Andersen JA. Lobular carcinoma in situ of the breast with ductal involvement: frequency and possible influence on prognosis. Acta Pathol Microbiol Scand [A]. 1974;82:655-662.
24. Andersen JA. Lobular carcinoma in situ: a histological study of 52 cases. Acta Pathol Microbiol Scand [A]. 1974;82:735-741.
25. Goldstein NS, Lacerna M, Vicini F. Cancerization of lobules and atypical ductal hyperplasia adjacent to ductal carcinoma in situ of the breast. Am J Clin Pathol. 1998;110:357-367.
26. Rimm DL, Sinard JH, Morrow JS. Reduced alpha-catenin and E-cadherin expression in breast cancer. Lab Invest. 1995; 72:506-512.
27. Bornslaeger EA, Corcoran CM, Stappenbeck TS, et al. Breaking the connection: displacement of the desmosomal plaque protein desmoplakin from cell-cell interfaces disrupts anchorage of intermediate filament bundles and alters intercellular junction assembly. J Cell Biol 1996;134:985-1001.
28. Leppa S, Vleminckx K, Van Roy F, et al. Syndecan-1 expression in mammary epithelial tumor cells is E-cadherin-dependent. J Cell Sci. 1996;109(Pt 6):1393-H03.
29. Tamura S. The E-cadherin-mediated cell-cell adhesion system in human cancers. Br J Surg. 1997;84:899-900.
30. Ozawa M, Kemler R. Altered cell adhesion activity by pervanadate due to the dissociation of alpha-catenin from the E-cadherin.catenin complex. J Biol Chem. 1998;273:6166-6170.
31. Steinberg MS, McNutt PM. Cadherins and their connections: adhesion junctions have broader functions. Curr Opin Cell Biol. 1999;11:554-560.
32. Wijnhoven BP, Pignatelli M. E-cadherin-catenin: more than a "sticky" molecular complex. Lancet. 1999;354:356-357.
33. Troxell ML, Gopalakrishnan S, McCormack J, et al. Inhibiting cadherin function by dominant mutant E-cadherin expression increases the extent of tight junction assembly. J Cell Sci. 2000;113(Pt 6):985-996.
34. von Schlippe M, Marshall JF, Perry P, et al. Functional interaction between E-cadherin and alpha-containing integrins in carcinoma cells. J Cell Sci. 2000;113(Pt 3):425-437.
35. Moll R, Mitze M, Frixen UH, et al. Differential loss of E-cadherin expression in infiltrating ductal and lobular breast carcinomas. Am J Pathol. 1993;143:1731-1742.
36. Gamallo C, Palacios J, Suarez A, et al. Correlation of E-cadherin expression with differentiation grade and histological type in breast carcinoma. Am J Pathol. 1993;142:987-993.
37. De Leeuw WJ, Berx G, Vos CB, et al. Simultaneous loss of E-cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in situ. J Pathol. 1997;183:404-411.
38. Hashizume R, Koizumi H, Ihara A, et al. Expression of beta-catenin in normal breast tissue and breast carcinoma: a comparative study with epithelial cadherin and alpha-catenin. Histopathology. 1996;29:139-146.
39. Vos CB, Cleton-Jansen AM, Berx G, et al. E-cadherin inactivation in lobular carcinoma in situ of the breast: an early event in tumorigenesis. Br J Cancer. 1997;76:1131-1133.
40. Bankfalvi A, Terpe HJ, Breukelmann D, et al. Immunophenotypic and prognostic analysis of E-cadherin and beta-catenin expression during breast carcinogenesis and tumour progression: a comparative study with CD44. Histopathology. 1999;34:25-34.
41. Lehr H-A, Folpe A, Yaziji H, et al. Cytokeratin 8 immunostaining pattern and E-cadherin expression distinguish lobular from ductal breast carcinoma. Am J Clin Pathol. 2000; 114:190-196.
42. Jacobs TW, Pliss N, Kouria G, et al. Carcinomas in situ (CIS) of the breast with indeterminate features: role of E-cadherin staining in categorization [abstract]. Mod Pathol. 2000;13:23A.
43. Ioffe O, Silverberg SG, Simsir A. Lobular lesions of the breast: immunohistochemical profile and comparison with ductal proliferations: E-cadherin expression in mixed ductal and lobular carcinomas of the breast [abstract]. Mod Pathol. 2000;13:23A.
44. Acs G, Lawton TJ, Livolsi VA, et al. Differential expression of E-cadherin in ductal and lobular carcinoma of the breast [abstract]. Mod Pathol. 2000;13:17A.
45. Norton AJ, Jordon S, Yeomans P. Brief, high-temperature heat denaturation (pressure cooking): a simple and effective method of antigen retrieval for routinely processed tissues. J Pathol. 1994;173:371-379.
46. Gown AM, Vogel AM. Monoclonal antibodies to human intermediate filament proteins, II: distribution of filament proteins in normal human tissues. Am J Pathol. 1984;114:309-321.
47. Lennington WJ, Jensen RA, Dalton LW, et al. Ductal carcinoma in situ of the breast: heterogeneity of individual lesions. Cancer. 1994;73:118-124.
48. Kestin LL, Goldstein NS, Lacerna MD, et al. Factors associated with local recurrence of mammographically detected ductal carcinoma in situ in patients given breast-conserving therapy. Cancer. 2000;88:596-607.
49. Goldstein NS, Kestin L, Vicini F. Pathologic features of initial biopsy specimens associated with residual intraductal carcinoma at re-excision in patients with ductal carcinoma in situ of the breast referred for breast conserving therapy. Am J Surg Pathol. 1999;23:1340-1348.